Mohammadi, Soheil
Gouravani, Mahdi
Salehi, Mohammad Amin
Arevalo, J. Fernando
Galetta, Steven L.
Harandi, Hamid
Frohman, Elliot M.
Frohman, Teresa C.
Saidha, Shiv
Sattarnezhad, Neda
Paul, Friedemann
Article History
Received: 18 November 2022
Accepted: 11 March 2023
First Online: 27 March 2023
Declarations
:
: Not applicable.
: Not applicable.
: Shiv Saidha has received consulting fees from Medical Logix for the development of CME programs in neurology and has served on scientific advisory boards for Biogen, Novartis, Genentech Corporation, TG therapeutics, Rewind therapeutics & Bristol Myers Squibb. He has performed consulting for Novartis, Genentech Corporation, JuneBrain LLC, and Lapix therapeutics. He is the PI of investigator-initiated studies funded by Genentech Corporation, Novartis, and Biogen. He previously received support from the Race to Erase MS foundation. He has received equity compensation for consulting from JuneBrain LLC and Lapix therapeutics. He was also the site investigator of trials sponsored by MedDay Pharmaceuticals, Clene Pharmaceuticals, and is the site investigator of a trial sponsored by Novartis. Dr. Sattarnezhad has received Sylvia Lawry Physician Fellowship award from National Multiple Sclerosis Society (NMSS). Elliot Frohman has received consulting and speaker fees from Biogen, Genzyme, Novartis, Alexion, Horizon, and Janssen. Soheil Mohammadi, Mahdi Gouravani, Mohammad Amin Salehi, J. Fernando Arevalo, Steven L. Galetta, Hamid Harandi, Teresa C Frohman, and Friedemann Paul report no disclosures.